Objective. The aim of this study was to evaluate the role of rituximab (RTX) in modulating the
expression of the IL-17/IL-23 pathway in the salivary glands (SGs) of patients with primary …

We read with great interest the recent contribution by Delli et al, 1 which aimed at
determining whether salivary gland histopathology could predict the response to rituximab in …

Sjögren's Syndrome (SS) is a chronic inflammatory disorder affecting exocrine glands, in
particular the lacrimal and salivary glands. The disease can be primary (pSS) or secondary …

In primary Sjögren's syndrome (pSS), FcRL4+ B cells are present in inflamed salivary gland
tissue, within or in close proximity to ductal epithelium. FcRL4 is also expressed by nearly all …

Objective To elucidate the pathologic role of follicular helper T (Tfh) cells and their subsets in
active, untreated IgG4‐related disease. Methods Fifteen patients with active, untreated …

Objectives Systemic sclerosis (SSc) is an autoimmune disease characterised by widespread
fibrosis, microangiopathy and autoantibodies. Follicular helper T (Tfh) cells CD4+ CXCR5+ …

The rationale for B cell depletion therapy with rituximab in primary Sjögren's syndrome relies
upon the well-established role of B cell hyperactivity in immunopathogenesis. In line with …

Objectives Growing evidence suggests that IL-17-producing T cells, lacking both CD4 and
CD8 molecules and defined as double negative (DN) cells, play a pivotal role in the …

Objective. Treatment with rituximab depletes B cells from the peripheral blood (PB) and
salivary glands (SGs) of patients with primary Sjögren's syndrome (SS). The purpose of this …

Recently, we reported elevated proportions of circulating follicular T helper cells and higher
levels of interleukin‐(IL‐) 21 in primary Sjögren's syndrome (pSS). Interaction of invariant …